12. INTERNATIONAL SUMMIT SCIENTIFIC RESEARCH CONGRESS, Gaziantep, Türkiye, 29 - 31 Mayıs 2024, ss.191-192
Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disease characterized by a decrease in the
number of platelets, an increase in megakaryocytes in the bone marrow, and a shortening of platelet
lifespan due to antiplatelet factors in the immunoglobulin G (IgG) structure.The second step of treatment
in ITP patients who do not respond to immunosuppressive treatment or whose course is severe is
splenectomy. Studies have shown that splenectomy provides a cure rate of 60-90%. Splenectomy was
first used in the treatment of ITP by Kaznelson in 1916. In this study, we aimed to evaluate the treatment
responses by examining the results of splenectomy treatment in patients followed in our clinic who did
not respond to first-line treatment. 22 patients who underwent splenectomy with the diagnosis of
idiopathic thrombocytopenic purpura between 2015 and 2023 were evaluated retrospectively. The
patients' age, gender, and platelet counts at 6 months and 1 year after splenectomy were examined. It
was examined whether the patients developed complications during surgery. 17 (77.2%) of the patients
were female and 5 (22.8%) were male. The mean age was 41.10±16.62 (16-72) years. All patients had
received steroid and immunosuppressive treatment before splenectomy. No serious complications were
observed in the intra-postoperative period in patients who underwent splenectomy. Platelet levels were
found to be normal in all patients at discharge. Loss of response was observed in two patients during
follow-up. In other patients, platelet levels were found to be within normal limits at both the 6th and 12th months.
Our results; It shows that splenectomy treatment is a safe treatment option in cases
unresponsive to medical treatment in the treatment of idiopathic thrombocytopenic purpura and that
long-term response can be achieved with splenectomy in these patients.
Keywords: Thrombocytopenia, splenectomy, response